- Home
- WVE vs NGD Comparison
WVE vs NGD Comparison
Compare WVE & NGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- NGD
- Stock Information
- Founded
- WVE 2012
- NGD N/A
- Country
- WVE Singapore
- NGD Canada
- Employees
- WVE N/A
- NGD N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- NGD
- Sector
- WVE Health Care
- NGD
- Exchange
- WVE Nasdaq
- NGD Nasdaq
- Market Cap
- WVE 915.6M
- NGD 3.8B
- IPO Year
- WVE 2015
- NGD 2004
- Fundamental
- Price
- WVE $6.95
- NGD $4.99
- Analyst Decision
- WVE Strong Buy
- NGD Buy
- Analyst Count
- WVE 13
- NGD 2
- Target Price
- WVE $20.15
- NGD $4.75
- AVG Volume (30 Days)
- WVE 1.0M
- NGD 25.4M
- Earning Date
- WVE 08-07-2025
- NGD 07-29-2025
- Dividend Yield
- WVE N/A
- NGD N/A
- EPS Growth
- WVE N/A
- NGD N/A
- EPS
- WVE N/A
- NGD 0.17
- Revenue
- WVE $104,939,000.00
- NGD $941,500,000.00
- Revenue This Year
- WVE N/A
- NGD $38.67
- Revenue Next Year
- WVE $1.94
- NGD $42.20
- P/E Ratio
- WVE N/A
- NGD $30.01
- Revenue Growth
- WVE N/A
- NGD 21.17
- 52 Week Low
- WVE $5.04
- NGD $1.94
- 52 Week High
- WVE $16.74
- NGD $5.16
- Technical
- Relative Strength Index (RSI)
- WVE 49.78
- NGD 62.75
- Support Level
- WVE $6.25
- NGD $4.78
- Resistance Level
- WVE $7.10
- NGD $5.16
- Average True Range (ATR)
- WVE 0.38
- NGD 0.17
- MACD
- WVE -0.02
- NGD -0.03
- Stochastic Oscillator
- WVE 52.15
- NGD 68.52
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.